Viral Vector and Plasmid DNA Manufacturing Industry Research Report 2023 - Global Forecast to 2028 - Ongoing Research on Viral Vector-Based Cell and Gene Therapies to Drive Growth
Company Logo
Company Logo

Viral Vector Manufacturing Market

Viral Vector Manufacturing Market
Viral Vector Manufacturing Market

Dublin, June 28, 2023 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

The global viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2%

The growth of this market can be attributed to the availability of funding for the development of gene therapy. Gene therapy is a rapidly growing field, and funding is needed for research and development, clinical trials, and manufacturing.

For instance, in December 2022, SonoThera, a biotechnology company announced the completion of its USD 60.75 million Series A financing round. The financing will support the continued development of SonoThera's ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.

The vector amplification, editing, and expansion segment accounted for the largest share by the upstream manufacturing process during the forecast period

In 2022, the vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process in the global viral vector and plasmid DNA manufacturing market. Vector amplification, editing, and expansion are critical steps in viral vector and plasmid DNA manufacturing as they directly impact the quantity, quality, and functionality of the vectors.

The pharmaceutical and biopharmaceutical industry is witnessing significant advancements, particularly in the development of novel therapeutics and vaccines. Viral vectors and plasmid DNA are crucial tools for delivering therapeutic genes or vaccine antigens.

The demand for vector amplification, editing, and expansion is driven by the need to produce a diverse range of viral vectors and plasmid DNA for various therapeutic and vaccine candidates.

Europe: The second largest region in the viral vector and plasmid DNA manufacturing market

Europe accounted for the second-largest market for viral vector and plasmid DNA manufacturing market after North America. The European viral vector and plasmid DNA manufacturing market has witnessed significant growth in recent years, driven by various factors that have propelled its expansion.

Europe is at the forefront of developing and adopting emerging technologies in the field of viral vector and plasmid DNA manufacturing market. This includes advancements in viral vector and plasmid DNA manufacturing technologies. The adoption of these innovative technologies accelerates the progress of viral vector and plasmid DNA manufacturing research and expands its applications.